AgomAb Therapeutics (NASDAQ:AGMB) Trading 5.4% Higher – Should You Buy?

AgomAb Therapeutics NV (NASDAQ:AGMB)’s share price shot up 5.4% during trading on Wednesday . The stock traded as high as $10.67 and last traded at $10.33. 97,030 shares changed hands during mid-day trading, a decline of 33% from the average session volume of 145,593 shares. The stock had previously closed at $9.80.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of AgomAb Therapeutics in a report on Tuesday, March 3rd. They set an “overweight” rating and a $32.00 price target for the company. Wall Street Zen upgraded AgomAb Therapeutics to a “hold” rating in a research note on Tuesday, February 17th. Zacks Research raised AgomAb Therapeutics to a “hold” rating in a research report on Wednesday, March 4th. Morgan Stanley began coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They set an “overweight” rating and a $28.00 price target for the company. Finally, Leerink Partners assumed coverage on shares of AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $36.00 price objective on the stock. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, AgomAb Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

AgomAb Therapeutics Trading Down 2.7%

The stock has a 50-day simple moving average of $10.99.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.